Biotie Therapies - Company Announcement

Biotie completes the issuance of convertible notes and warrants

BIOTIE THERAPIES CORP.            STOCK EXCHANGE RELEASE           29 May 2015
at 8.30 a.m.

Biotie completes the issuance of convertible notes and warrants

Biotie Therapies Corp. (the "Company" or "Biotie") announced on 23 April 2015
its plans to strengthen its capital structure by approximately EUR 95 million
through a directed issue of convertible promissory notes (the "Convertible
Notes") and warrants (the "Warrants") to certain US investors and certain
existing shareholders, as well as a US public offering (the "US IPO") and
potential other offerings in connection with the US IPO.

Biotie has completed the issuance of in total 220,400,001 Convertible Notes and
220,400,001 Warrants to certain US investors and certain existing shareholders
pursuant to the authorisation granted by the Annual General Meeting of the
Company on 26 May 2015. The total principal amount raised from the issuance of
the Convertible Notes was EUR 33.06 million. The Warrants were issued free of
charge to the subscribers of the Convertible Notes. Under the Convertible Notes
and Warrants, a total number of 440,800,002 shares may be issued.

The Convertible Notes have a conversion price of EUR 0.15 per share and can be
converted by their holders at any time prior to their repayment. The Convertible
Notes automatically convert into new shares in the Company upon completion of
the US IPO and, should the US IPO not take place, the Company can force the
conversion of the Convertible Notes at any time after 1 May 2016. The
Convertible Notes can be repaid by the Company on or after 1 May 2035 if, and to
the extent, they have not been converted. Each Warrant entitles its holder to
subscribe for one new or treasury share in the Company at a subscription price
of EUR 0.17. The Warrants, irrespective of the contemplated US IPO, may be
exercised for a period of five (5) years from a date falling five (5) months
after their issuance. The terms and conditions of the Convertible Notes and the
Warrants will be available on the Company's website.

Turku, 29 May 2015

Biotie Therapies Corp.

Timo Veromaa
President and CEO

For further information, please contact:

David Cook, CFO
Tel. +358 2 2748 900, e-mail: david.cook@biotie.com

DISTRIBUTION:

NASDAQ OMX Helsinki Ltd
Main Media

www.biotie.com


[HUG#1924858]